Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Dyslipidemia

Free Subscription 04.11.2019 31 Atherosclerosis 2 N Engl J Med

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Atherosclerosis

1. SHEK A, Alieva R, Kurbanov R, Hoshimov S, et al
   Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle.
   Atherosclerosis. 2018;277:524-529.
   PubMed     Text format     Abstract available
   
   
2. TRUONG TH, Kim NT, Nguyen MNT, Pang J, et al
   Homozygous familial hypercholesterolaemia in Vietnam: Case series, genetics and cascade testing of families.
   Atherosclerosis. 2018;277:392-398.
   PubMed     Text format     Abstract available
   
   
3. GROSELJ U, Kovac J, Sustar U, Mlinaric M, et al
   Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review.
   Atherosclerosis. 2018;277:383-391.
   PubMed     Text format     Abstract available
   
   
4. PAYNE J, Williams S, Maxwell D, Pariente MT, et al
   Familial hypercholesterolaemia patient support groups and advocacy: A multinational perspective.
   Atherosclerosis. 2018;277:377-382.
   PubMed     Text format     Abstract available
   
   
5. DESCAMPS OS, Van Caenegem O, Hermans MP, Balligand JL, et al
   A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent cascade screening and treatment: BEL-FaHST (The BELgium Familial Hypercholesterolaemia STrategy).
   Atherosclerosis. 2018;277:369-376.
   PubMed     Text format     Abstract available
   
   
6. HARADA-SHIBA M, Ako J, Arai H, Hirayama A, et al
   Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: Results of the EXPLORE-J study.
   Atherosclerosis. 2018;277:362-368.
   PubMed     Text format     Abstract available
   
   
7. VRABLIK M, Raslova K, Vohnout B, Blaha V, et al
   Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
   Atherosclerosis. 2018;277:355-361.
   PubMed     Text format     Abstract available
   
   
8. LATKOVSKIS G, Saripo V, Gilis D, Nesterovics G, et al
   Latvian registry of familial hypercholesterolemia: The first report of three-year results.
   Atherosclerosis. 2018;277:347-354.
   PubMed     Text format     Abstract available
   
   
9. KAYIKCIOGLU M, Tokgozoglu L, Dogan V, Ceyhan C, et al
   What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)?
   Atherosclerosis. 2018;277:341-346.
   PubMed     Text format     Abstract available
   
   
10. BELIARD S, Boccara F, Cariou B, Carrie A, et al
    High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.
    Atherosclerosis. 2018;277:334-340.
    PubMed     Text format     Abstract available
    
    
11. VAN DELDEN XM, Huijgen R, Wolmarans KH, Brice BC, et al
    LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C.
    Atherosclerosis. 2018;277:327-333.
    PubMed     Text format     Abstract available
    
    
12. VOHNOUT B, Fabryova L, Klabnik A, Kadurova M, et al
    Treatment pattern of familial hypercholesterolemia in Slovakia: Targets, treatment and obstacles in common practice.
    Atherosclerosis. 2018;277:323-326.
    PubMed     Text format     Abstract available
    
    
13. SCHMIDT N, Dressel A, Grammer TB, Gouni-Berthold I, et al
    Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry.
    Atherosclerosis. 2018;277:314-322.
    PubMed     Text format     Abstract available
    
    
14. RIZOS CV, Elisaf MS, Skoumas I, Tziomalos K, et al
    Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).
    Atherosclerosis. 2018;277:308-313.
    PubMed     Text format     Abstract available
    
    
15. WAKE M, Onishi Y, Guelfucci F, Oh A, et al
    Treatment patterns in hyperlipidaemia patients based on administrative claim databases in Japan.
    Atherosclerosis. 2018;272:145-152.
    PubMed     Text format     Abstract available
    
    
16. BRETT T, Qureshi N, Gidding S, Watts GF, et al
    Screening for familial hypercholesterolaemia in primary care: Time for general practice to play its part.
    Atherosclerosis. 2018;277:399-406.
    PubMed     Text format     Abstract available
    
    
17. PETRULIONIENE Z, Gargalskaite U, Kutkiene S, Staigyte J, et al
    Establishing a national screening programme for familial hypercholesterolaemia in Lithuania.
    Atherosclerosis. 2018;277:407-412.
    PubMed     Text format     Abstract available
    
    
18. MEHTA R, Martagon AJ, Galan Ramirez GA, Gonzalez Retana G, et al
    The development of the Mexican Familial Hypercholesterolemia (FH) National Registry.
    Atherosclerosis. 2018;277:517-523.
    PubMed     Text format     Abstract available
    
    
19. AZRAII AB, Ramli AS, Ismail Z, Abdul-Razak S, et al
    Knowledge, awareness and practice regarding familial hypercholesterolaemia among primary care physicians in Malaysia: The importance of professional training.
    Atherosclerosis. 2018;277:508-516.
    PubMed     Text format     Abstract available
    
    
20. BOTHA TC, Pilcher GJ, Wolmarans K, Blom DJ, et al
    Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies.
    Atherosclerosis. 2018;277:502-507.
    PubMed     Text format     Abstract available
    
    
21. HAGGER MS, Hardcastle SJ, Hu M, Kwok S, et al
    Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia.
    Atherosclerosis. 2018;277:493-501.
    PubMed     Text format     Abstract available
    
    
22. RAAL FJ, Hovingh GK, Catapano AL
    Familial hypercholesterolemia treatments: Guidelines and new therapies.
    Atherosclerosis. 2018;277:483-492.
    PubMed     Text format     Abstract available
    
    
23. AFANASIEVA OI, Ezhov MV, Razova OA, Afanasieva MI, et al
    Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Atherosclerosis. 2018;277:477-482.
    PubMed     Text format     Abstract available
    
    
24. PANG J, David Marais A, Blom DJ, Brice BC, et al
    Heterozygous familial hypercholesterolaemia in specialist centres in South Africa, Australia and Brazil: Importance of early detection and lifestyle advice.
    Atherosclerosis. 2018;277:470-476.
    PubMed     Text format     Abstract available
    
    
25. SOUTO AC, Miname MH, Fukushima J, Jannes CE, et al
    Health related quality of life in individuals at high risk for familial hypercholesterolemia undergoing genetic cascade screening in Brazil.
    Atherosclerosis. 2018;277:464-469.
    PubMed     Text format     Abstract available
    
    
26. FUTEMA M, Bourbon M, Williams M, Humphries SE, et al
    Clinical utility of the polygenic LDL-C SNP score in familial hypercholesterolemia.
    Atherosclerosis. 2018;277:457-463.
    PubMed     Text format     Abstract available
    
    
27. ALVES AC, Benito-Vicente A, Medeiros AM, Reeves K, et al
    Further evidence of novel APOB mutations as a cause of familial hypercholesterolaemia.
    Atherosclerosis. 2018;277:448-456.
    PubMed     Text format     Abstract available
    
    
28. HSIUNG YC, Lin PC, Chen CS, Tung YC, et al
    Identification of a novel LDLR disease-causing variant using capture-based next-generation sequencing screening of familial hypercholesterolemia patients in Taiwan.
    Atherosclerosis. 2018;277:440-447.
    PubMed     Text format     Abstract available
    
    
29. LOPEZ G, Bernal LM, Gelvez N, Gomez LF, et al
    Mutational analysis of the LDLR gene in a cohort of Colombian families with familial hypercholesterolemia.
    Atherosclerosis. 2018;277:434-439.
    PubMed     Text format     Abstract available
    
    
30. ALNOURI F, Athar M, Al-Allaf FA, Abduljaleel Z, et al
    Novel combined variants of LDLR and LDLRAP1 genes causing severe familial hypercholesterolemia.
    Atherosclerosis. 2018;277:425-433.
    PubMed     Text format     Abstract available
    
    
31. BRUNHAM LR, Ruel I, Khoury E, Hegele RA, et al
    Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry.
    Atherosclerosis. 2018;277:419-424.
    PubMed     Text format     Abstract available
    
    

    
    N Engl J Med

32. MICHOS ED, McEvoy JW, Blumenthal RS
    Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease.
    N Engl J Med. 2019;381:1557-1567.
    PubMed     Text format    
    
    
33. LUIRINK IK, Wiegman A, Kusters DM, Hof MH, et al
    20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia.
    N Engl J Med. 2019;381:1547-1556.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Dyslipidemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: